Renovacor announces the appointment of Matt Killeen, Ph.D., as Scientific Director
PHILADELPHIA, Aug 25, 2021 (GLOBE NEWSWIRE) – Renovacor, Inc. (“Renovacor”), an early-stage biotechnology company developing adeno-associated virus (AAV) gene therapies for devastating cardiovascular diseases and of the central nervous system resulting from BAG3 genetic variants, today announced the appointment of Matt Killeen, Ph.D., as Scientific Director (CSO), effective September 1, 2021.
“Matt’s extensive experience in the discovery, research and development of AAV-based gene therapies for cardiovascular disease makes him an ideal candidate as a CSO of Renovacor,” said Magdalene Cook, MD, chief executive officer. the management of Renovacor. “He has an impressive track record of successfully building R&D capabilities, promoting drug candidates and building an early stage pipeline, which positions him well for success in his new role. We are delighted to welcome him to the team and look forward to working together to advance REN-001 in the clinic and further develop our broader portfolio of innovative gene therapies.
Dr Killeen added, “Renovacor’s early pipeline development leadership presents a transformational opportunity to positively impact the lives of patients living with it. BAG-3 Associated dilated cardiomyopathy and larger patient populations. I believe the company’s unique therapeutic approach has broad applicability and the potential to produce the first FDA-approved therapeutic intervention to address the underlying genetic cause of BAG3-associated familial dilated cardiomyopathy. His impressive preclinical data sets strongly support this belief and underscore how REN-001’s validated capsid, unique payload, and monogenic target indication positions him for success. I look forward to working with the Renovacor team and its respected scientific and clinical advisors to leverage this data as we seek to provide transformative treatments for patients living with devastating illnesses.
Dr Killeen joins Renovacor from BioMarin Pharmaceutical Inc. where, as head of cardiovascular research, he led the discovery and early development of new AAV-based gene therapies for a range of inherited heart diseases. At BioMarin, Dr. Killeen founded the cardiovascular therapeutics field and transformed it into a dedicated R&D unit, built a pipeline of potential precision therapies for genetic heart disease, and forged multiple industry R&D partnerships. and academia. In previous roles at BioMarin, he led the R&D portfolio strategy initiatives for the company’s first pipeline and led the development of its R&D strategy. Prior to joining BioMarin, Dr. Killeen led efforts to support the commercialization and launch of new therapies for multiple sclerosis at Biogen. He has also advised pharmaceutical companies on R&D and commercialization strategies for multiple pipeline therapies for cardiovascular disease at Decision Resources Group, now Clarivate.
Dr Killeen holds a doctorate. in Cardiac Electrophysiology from the University of Cambridge, where he specialized in genetic abnormalities of the heart rhythm and identified potential new therapeutic approaches for these diseases. He then worked as a researcher at Harvard Medical School and Massachusetts General Hospital in Calum MacRae’s lab, studying the biology of rare and common heart disease. He has published over 20 peer-reviewed articles on topics covering genetic heart disease, cardiac electrophysiology, arrhythmias, and drug safety, and is the sole author of a textbook on the role of cardiac electrophysiology in pharmaceutical R&D. Dr Killeen is a member of the Board of Trustees of the Sudden Cardiac Arrest Foundation and has been elected a Fellow of the Royal Society of Biology (FRSB) and a Fellow of the American College of Cardiology (FACC).
Renovacor is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 diseases associated with gene mutations in areas with high unmet medical needs. The therapeutic orientation of Renovacor is initially focused on cardiovascular diseases, with a program of BAG3 dilated cardiomyopathy associated with a mutation. For more information, please visit www.renovacor.com. No part of the Renovacor website is incorporated by reference or otherwise considered to be part of this press release.
Renovacor previously announced that it has entered into a merger agreement with Chardan Healthcare Acquisition 2 Corp. (“CHAQ”), a special purpose acquisition company. Completion of the proposed merger is subject to the approval of the shareholders of CHAQ and certain other conditions. The proposed merger is expected to be finalized in the third quarter of 2021.
About Chardan Healthcare Acquisition Corp.
CHAQ is a special purpose acquisition company incorporated for the purpose of carrying out a merger, acquisition or similar business combination. CHAQ raised approximately $ 86.0 million in April 2020 for the purpose of combining with a public or private operating company. CHAQ was founded and sponsored by affiliates of Chardan Capital Markets LLC. CHAQ is Chardan’s sixth listed acquisition vehicle.
Additional information and where to find it
This communication is made with respect to a proposed transaction between Renovacor and CHAQ. This document does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor will there be any sale of securities in any jurisdiction in which any such offer, sale or exchange would be illegal prior to registration or qualification under the securities laws of such jurisdiction. CHAQ intends to file a proxy, which will be sent to all shareholders of CHAQ and Renovacor. CHAQ will also file other documents relating to the proposed transaction with the Securities and Exchange Commission (the “SEC”). BEFORE TAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS OF CHAQ AND RENOVACOR ARE INVITED TO READ THE PROXY STATEMENT, AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND ALL OTHER RELEVANT DOCUMENTS SUBMITTED OR THAT WILL BE FILED WITH SEC THE PROPOSED TRANSACTION AS THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND PARTS THEREOF.
Investors and securityholders will be able to obtain free copies of the Proxy Circular and all other relevant documents filed or to be filed with the SEC by the CHAQ through the website maintained by the SEC at www.sec.gov. In addition, documents filed by the CHAQ can be obtained free of charge on the CHAQ website at the address https://www.chardanhealthcarespac.com/ or by written request to CHAQ at Chardan Healthcare Acquisition 2 Corp., 17 State Street, 21st Floor, New York, NY 10004.
Participants in the solicitation
CHAQ and Renovacor and their respective directors and officers may be considered participants in the solicitation of proxies from the shareholders of CHAQ in connection with the proposed transaction. Information on the directors and officers of CHAQ and their ownership of the securities of CHAQ is presented in documents filed by CHAQ with the SEC, including CHAQ’s annual report on Form 10-K for the fiscal year ended December 31. 2020, which was filed with the SEC in March. 4, 2021. To the extent that CHAQ’s holdings of securities have changed from the amounts printed in CHAQ’s annual report on Form 10-K for the fiscal year ended December 31, 2020, which was filed with the SEC on March 4, 2021, the changes have been or will be reflected on the change of ownership statements on Form 4 filed with the SEC. Additional information regarding the interests of such persons and other persons who may be considered participants in the proposed transaction may be obtained by reading the proxy circular relating to the proposed transaction when it becomes available. You can get free copies of these documents as described in the paragraph above.
Legend of forward-looking statements
This communication contains certain forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the expected timing of the transaction and the current Renovacor products. of development. These forward-looking statements are generally identified by the words “believe”, “plan”, “expect”, “anticipate”, “estimate”, “intend”, “the strategy”, “the future”, “The opportunity”, “the plan,” “may”, “should”, “will”, “would”, “will”, “will continue”, “will probably result” and similar expressions. Forward-looking statements are predictions, projections and other statements regarding future events that are based on current expectations and assumptions and, therefore, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements contained in this communication. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of CHAQ’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Proxy Circular discussed above and other filings. by CHAQ from time to time with the SECOND. These documents identify and discuss important risks and uncertainties that could cause actual events and results to differ materially from those contained in forward-looking statements. Forward-looking statements speak only as of the date on which they are made. Readers are cautioned not to place undue reliance on forward-looking statements, and Renovacor and CHAQ assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Neither Renovacor nor CHAQ guarantees that Renovacor or CHAQ will meet its expectations.